Rex­ahn inks Keytru­da com­bo col­lab­o­ra­tion in breast can­cer; Achillion hires uniQure's Steven Ze­lenkofske as new CMO

→ Rex­ahn Phar­ma has scored the lat­est spot on Mer­ck’s ever ex­pand­ing list of part­ners for its Keytru­da fran­chise. The Rockville, MD-based biotech $RNN is pay­ing for the Phase II tri­al, in which re­searchers will test Mer­ck’s PD-1 star with their RX-5902 in pa­tients with triple neg­a­tive breast can­cer. RX-5902 in­hibits phos­pho­ry­lat­ed-p68, there­by — ac­cord­ing to Rex­ahn — mod­u­lat­ing the β-catenin/Wnt path­way. A sep­a­rate PhII study of the drug as a monother­a­py is on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER